File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/j.1467-789X.2009.00651.x
- Scopus: eid_2-s2.0-77954748599
- PMID: 19922432
- WOS: WOS:000280968900005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Efficacy and safety of anti-obesity drugs in children and adolescents: Systematic review and meta-analysis: Obesity management
Title | Efficacy and safety of anti-obesity drugs in children and adolescents: Systematic review and meta-analysis: Obesity management |
---|---|
Authors | |
Keywords | Anti-obesity drug child pharmacotherapy systematic review |
Issue Date | 2010 |
Publisher | Blackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/OBR |
Citation | Obesity Reviews, 2010, v. 11 n. 8, p. 593-602 How to Cite? |
Abstract | We undertook a meta-analysis of randomized controlled trials to summarize the efficacy of anti-obesity drugs in reducing BMI and improving health in children and adolescents. Data sources included Medline, Embase, the Cochrane controlled trials register and other registers of controlled trials, together with reference lists of identified articles. All data sources were searched from January 1996 to July 2008. We searched for double blind randomized placebo controlled trials of approved anti-obesity drugs used in children and adolescents (age <20) with primary obesity for ≥6 months. Six trials, 4 of sibutramine (total patients = 686) and 2 of orlistat (n = 573) met inclusion criteria. No trials of rimonabant were identified. Compared with placebo, sibutramine together with behavioural support reduced BMI by 2.20 kg/m 2 (95% CI: 1.57 to 2.83) and orlistat together with behavioural support reduced BMI by 0.83 kg/m 2 (95% CI 0.47 to 1.19). Sibutramine improved waist circumference, triglycerides and high density lipoprotein (HDL)-cholesterol, but raised systolic and diastolic blood pressure and pulse. Orlistat increased rates of gastrointestinal side-effects. We conclude that sibutramine in adolescents produces clinically meaningful reductions in BMI and waist circumference of approximately 0.63 SD, with improvements in cardiometabolic risk. Orlistat modestly reduces BMI (effect size approximately 0.24 SD) with a high prevalence of gastrointestinal adverse effects. © 2009 International Association for the Study of Obesity. |
Persistent Identifier | http://hdl.handle.net/10722/171404 |
ISSN | 2023 Impact Factor: 8.0 2023 SCImago Journal Rankings: 2.818 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Viner, RM | en_US |
dc.contributor.author | Hsia, Y | en_US |
dc.contributor.author | Tomsic, T | en_US |
dc.contributor.author | Wong, ICK | en_US |
dc.date.accessioned | 2012-10-30T06:13:56Z | - |
dc.date.available | 2012-10-30T06:13:56Z | - |
dc.date.issued | 2010 | en_US |
dc.identifier.citation | Obesity Reviews, 2010, v. 11 n. 8, p. 593-602 | en_US |
dc.identifier.issn | 1467-7881 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/171404 | - |
dc.description.abstract | We undertook a meta-analysis of randomized controlled trials to summarize the efficacy of anti-obesity drugs in reducing BMI and improving health in children and adolescents. Data sources included Medline, Embase, the Cochrane controlled trials register and other registers of controlled trials, together with reference lists of identified articles. All data sources were searched from January 1996 to July 2008. We searched for double blind randomized placebo controlled trials of approved anti-obesity drugs used in children and adolescents (age <20) with primary obesity for ≥6 months. Six trials, 4 of sibutramine (total patients = 686) and 2 of orlistat (n = 573) met inclusion criteria. No trials of rimonabant were identified. Compared with placebo, sibutramine together with behavioural support reduced BMI by 2.20 kg/m 2 (95% CI: 1.57 to 2.83) and orlistat together with behavioural support reduced BMI by 0.83 kg/m 2 (95% CI 0.47 to 1.19). Sibutramine improved waist circumference, triglycerides and high density lipoprotein (HDL)-cholesterol, but raised systolic and diastolic blood pressure and pulse. Orlistat increased rates of gastrointestinal side-effects. We conclude that sibutramine in adolescents produces clinically meaningful reductions in BMI and waist circumference of approximately 0.63 SD, with improvements in cardiometabolic risk. Orlistat modestly reduces BMI (effect size approximately 0.24 SD) with a high prevalence of gastrointestinal adverse effects. © 2009 International Association for the Study of Obesity. | en_US |
dc.language | eng | en_US |
dc.publisher | Blackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/OBR | en_US |
dc.relation.ispartof | Obesity Reviews | en_US |
dc.subject | Anti-obesity drug | - |
dc.subject | child | - |
dc.subject | pharmacotherapy | - |
dc.subject | systematic review | - |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Anti-Obesity Agents - Adverse Effects - Therapeutic Use | en_US |
dc.subject.mesh | Appetite Depressants - Adverse Effects - Therapeutic Use | en_US |
dc.subject.mesh | Body Mass Index | en_US |
dc.subject.mesh | Child | en_US |
dc.subject.mesh | Cognitive Therapy | en_US |
dc.subject.mesh | Combined Modality Therapy | en_US |
dc.subject.mesh | Consumer Product Safety | en_US |
dc.subject.mesh | Cyclobutanes - Adverse Effects - Therapeutic Use | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Lactones - Adverse Effects - Therapeutic Use | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Obesity - Drug Therapy | en_US |
dc.subject.mesh | Randomized Controlled Trials As Topic | en_US |
dc.subject.mesh | Treatment Outcome | en_US |
dc.subject.mesh | Waist Circumference - Drug Effects | en_US |
dc.subject.mesh | Weight Loss | en_US |
dc.title | Efficacy and safety of anti-obesity drugs in children and adolescents: Systematic review and meta-analysis: Obesity management | en_US |
dc.type | Article | en_US |
dc.identifier.email | Wong, ICK:wongick@hku.hk | en_US |
dc.identifier.authority | Wong, ICK=rp01480 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1111/j.1467-789X.2009.00651.x | en_US |
dc.identifier.pmid | 19922432 | - |
dc.identifier.scopus | eid_2-s2.0-77954748599 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-77954748599&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 11 | en_US |
dc.identifier.issue | 8 | en_US |
dc.identifier.spage | 593 | en_US |
dc.identifier.epage | 602 | en_US |
dc.identifier.isi | WOS:000280968900005 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Viner, RM=7005899067 | en_US |
dc.identifier.scopusauthorid | Hsia, Y=35068032100 | en_US |
dc.identifier.scopusauthorid | Tomsic, T=36553535400 | en_US |
dc.identifier.scopusauthorid | Wong, ICK=7102513915 | en_US |
dc.identifier.citeulike | 7601065 | - |
dc.identifier.issnl | 1467-7881 | - |